GO:0004177 aminopeptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004177 aminopeptidase activity describes the catalysis of hydrolysis of a single N-terminal amino acid residue from a polypeptide chain.
• Aminopeptidase activity is measurable in diverse human tissues, including nasal mucosa, brain, and lymphoid tissues, and is altered in several disease states.
• Multiple distinct enzymes contribute to cellular aminopeptidase activity, including cytosolic, membrane-bound, and high-molecular-weight forms.
• A conserved tyrosine residue is essential for the catalytic activity of aminopeptidase A, illustrating mechanistic conservation among M1 family members.
• Altered aminopeptidase activity has been linked to chronic renal failure, heroin addiction, and inflammatory airway conditions.
• CRISPR-based knockout, point-mutation, and overexpression models enable causal dissection of individual aminopeptidase genes.
Description
Aminopeptidase activity (GO:0004177) is a fundamental molecular function defined as the catalysis of hydrolysis of a single N-terminal amino acid residue from a polypeptide chain. This activity is executed by a diverse group of enzymes that trim peptides and proteins at their amino termini, thereby contributing to protein maturation, peptide hormone processing, antigen presentation, and general protein turnover. The importance of this activity is underscored by its presence across human tissues: aminopeptidase activity has been detected in human nasal mucosa, in the postmortem brain of heroin addicts, and in adenoid and tonsillar tissues. Beyond baseline physiology, aminopeptidase activity is dynamically regulated in disease. For example, experimental chronic renal failure in rats alters hepatic aminopeptidase activity, and a census of cytosolic aminopeptidase activity in mammalian cells revealed two novel cytosolic aminopeptidases, expanding the known repertoire of these enzymes. At the molecular level, a tyrosine residue essential for catalytic activity has been identified in aminopeptidase A, providing a structural basis for understanding the catalytic mechanism of this enzyme class. For researchers, GO:0004177 provides a unifying functional annotation that links biochemically distinct enzymes—such as aminopeptidase A, aminopeptidase B, pyroglutamyl peptidase I, and high-molecular-weight aminopeptidases—under a single catalytic concept. This annotation is critical for interpreting omics data, designing enzyme assays, and developing therapeutic modulators, as exemplified by recent efforts to synthesize diaryl ether modulators of the leukotriene A4 hydrolase aminopeptidase activity.
aminopeptidase activity At A Glance
| GO ID | GO:0004177 |
|---|---|
| GO term | aminopeptidase activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain. |
| Major function | Proteolytic removal of N-terminal amino acids from peptides and proteins |
| Representative enzymes | Aminopeptidase A, aminopeptidase B, pyroglutamyl peptidase I, leukotriene A4 hydrolase, cytosolic aminopeptidases |
| Tissue distribution | Detected in nasal mucosa, brain, adenoids, tonsils, and liver |
| Disease relevance | Inflammatory airway disease, chronic renal failure, heroin addiction, cancer |
What Is GO:0004177?
GO:0004177 aminopeptidase activity is defined as the catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain. In other words, it is the enzymatic removal of the first amino acid from the amino terminus of a peptide or protein substrate. This activity is classified under the molecular_function ontology aspect and is carried out by a wide range of enzymes that share this catalytic capability but may differ in substrate specificity, cellular localization, and regulatory properties.
Why Is aminopeptidase activity Important in Cell Biology?
Aminopeptidase activity is important because it governs the stability, maturation, and function of a vast array of peptides and proteins, and its dysregulation is associated with human disease. The activity has been documented in multiple human tissues and pathological states, including nasal mucosa, hyperplastic adenoids and tonsils, and the brain of heroin addicts. In experimental models, hepatic aminopeptidase activity changes in chronic renal failure, suggesting a role in metabolic adaptation. The discovery of novel cytosolic aminopeptidases highlights that this activity is more widespread than previously appreciated. Furthermore, the essential catalytic tyrosine in aminopeptidase A and the development of modulators targeting leukotriene A4 hydrolase aminopeptidase activity demonstrate the therapeutic potential of understanding this function at the molecular level.
• Aminopeptidase activity is required for the final steps of protein degradation and peptide turnover.
• It contributes to the processing of peptide hormones and neurotransmitters.
• Altered aminopeptidase activity is observed in inflammatory airway diseases such as adenoid hyperplasia and chronic tonsillitis.
• Hepatic aminopeptidase activity is modified in experimental chronic renal failure.
• Brain aminopeptidase activity is altered in heroin addicts, linking it to neuroadaptive processes.
• Cytosolic aminopeptidases expand the functional repertoire of intracellular peptide trimming.
• A conserved tyrosine residue is essential for catalysis in aminopeptidase A, providing a target for mechanistic studies.
• High-molecular-weight aminopeptidases represent distinct mammalian enzymes with potential unique roles.
• Leukotriene A4 hydrolase aminopeptidase activity can be modulated by small molecules, indicating druggability.
• Aminopeptidase activity in nasal mucosa may influence local peptide signaling and host defense.
What Happens During aminopeptidase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs the end of a protein or peptide chain.
Aminopeptidases recognize the free alpha-amino group of the N-terminal amino acid of a polypeptide substrate. This binding positions the first peptide bond for hydrolysis. The specificity for the N-terminal residue varies among enzymes; for example, aminopeptidase A preferentially cleaves acidic residues, while aminopeptidase B prefers basic residues. The catalytic pocket contains residues that stabilize the substrate and orient the scissile bond. In aminopeptidase A, a tyrosine residue is essential for this catalytic activity.
Catalytic hydrolysis of the N-terminal peptide bond
In simple terms: The enzyme cuts off the first amino acid.
Once bound, the enzyme catalyzes the hydrolysis of the peptide bond between the N-terminal residue and the rest of the chain. This reaction releases a free amino acid and a shortened peptide. The mechanism typically involves a metal ion (often zinc) that activates a water molecule for nucleophilic attack. The essential tyrosine in aminopeptidase A likely participates in proton transfer or stabilization of the transition state. This hydrolytic step is the defining feature of GO:0004177.
Product release and enzyme turnover
In simple terms: The cut pieces are released and the enzyme is ready to work again.
After hydrolysis, the free amino acid and the truncated peptide are released from the active site, allowing the enzyme to bind a new substrate. The efficiency of this turnover can vary widely among aminopeptidases. For instance, high-molecular-weight aminopeptidases may have distinct kinetic properties. The overall rate of aminopeptidase activity in a cell or tissue reflects the combined action of multiple enzymes, as seen in the complex profiles observed in human nasal mucosa and brain.
Cellular context and regulation of activity
In simple terms: The cell controls where and when these enzymes work.
Aminopeptidase activity is not uniform across cellular compartments. Cytosolic aminopeptidases contribute to the degradation of intracellular peptides, while membrane-bound forms such as aminopeptidase B and pyroglutamyl peptidase I act at the cell surface or in specific organelles. The activity can be regulated by changes in enzyme expression, post-translational modifications, or the availability of substrates and cofactors. In disease states such as chronic renal failure or heroin addiction, the overall aminopeptidase activity in tissues like liver and brain is altered, indicating physiological regulation.
Key Genes Involved in GO:0004177 aminopeptidase activity
The following genes encode enzymes that exhibit aminopeptidase activity (GO:0004177) or are directly involved in its regulation and measurement.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ENPEP | Encodes aminopeptidase A, a membrane-bound enzyme that cleaves acidic N-terminal residues | Essential tyrosine for catalysis identified; studied in hypertension and renal disease |
| ANPEP | Encodes aminopeptidase N (CD13), a membrane-bound enzyme with broad specificity | Marker in leukemia and angiogenesis; target for drug development |
| LNPEP | Encodes leucyl/cystinyl aminopeptidase (insulin-regulated aminopeptidase) | Role in glucose uptake and memory; studied in Alzheimer's disease |
| RNPEP | Encodes arginyl aminopeptidase (aminopeptidase B) | Involved in peptide hormone processing; activity measured in tonsillar tissue |
| PGPEP1 | Encodes pyroglutamyl peptidase I | Removes N-terminal pyroglutamate; activity measured in adenoid and tonsillar hyperplasia |
| LTA4H | Encodes leukotriene A4 hydrolase, which has aminopeptidase activity | Modulators of its aminopeptidase activity synthesized; role in inflammation |
| NPEPPS | Encodes puromycin-sensitive aminopeptidase | Cytosolic aminopeptidase; involved in protein turnover and neurodegeneration |
| ERAP1 | Encodes endoplasmic reticulum aminopeptidase 1 | Trims peptides for MHC class I presentation; linked to autoimmunity |
| ERAP2 | Encodes endoplasmic reticulum aminopeptidase 2 | Peptide trimming in antigen presentation; disease associations |
| METAP1 | Encodes methionine aminopeptidase 1 | Removes initiator methionine; target in cancer |
| METAP2 | Encodes methionine aminopeptidase 2 | Removes initiator methionine; anti-angiogenic target |
| XPNPEP1 | Encodes X-prolyl aminopeptidase 1 | Cleaves N-terminal X-Pro dipeptides; involved in peptide metabolism |
| XPNPEP2 | Encodes X-prolyl aminopeptidase 2 | Membrane-bound; role in blood pressure regulation |
| NPEPL1 | Encodes aminopeptidase-like 1 | Novel cytosolic aminopeptidase identified in census |
| CNDP1 | Encodes carnosine dipeptidase 1 | Related to aminopeptidase activity; studied in diabetic nephropathy |
| CNDP2 | Encodes carnosine dipeptidase 2 | Cytosolic peptidase with broad specificity |
| DPEP1 | Encodes dipeptidase 1 | Related to aminopeptidase activity; role in kidney and cancer |
How Is aminopeptidase activity Regulated?
Aminopeptidase activity is regulated at multiple levels. Enzyme expression can be induced or repressed by physiological and pathological stimuli; for example, hepatic aminopeptidase activity changes in experimental chronic renal failure, and brain aminopeptidase activity is altered in heroin addicts. At the protein level, post-translational modifications and interactions with inhibitors or activators can modulate catalytic efficiency. The essential tyrosine residue in aminopeptidase A highlights that single amino acid changes can abolish activity. Additionally, the presence of multiple aminopeptidases with overlapping specificities suggests that their activities are coordinated to prevent excessive peptide degradation. Small-molecule modulators, such as diaryl ether compounds targeting leukotriene A4 hydrolase aminopeptidase activity, demonstrate that pharmacological regulation is feasible.
aminopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ENPEP | Hypertension and renal disease | Knockout mouse or CRISPR point mutation of catalytic tyrosine |
| LTA4H | Inflammation and cardiovascular disease | Overexpression or point mutation to separate aminopeptidase from epoxide hydrolase activity |
| ANPEP | Leukemia and angiogenesis | Knockout cell lines and xenograft models |
| ERAP1 | Autoimmune diseases (e.g., ankylosing spondylitis) | Knock-in of disease-associated variants in cell lines |
| NPEPPS | Neurodegeneration | Knockout neurons and overexpression models |
Aminopeptidase activity in inflammatory airway diseases
Altered aminopeptidase activity has been observed in adenoid hyperplasia, tonsillar hyperplasia, and chronic tonsillitis. Specifically, the activity of soluble aminopeptidase A and dipeptidyl peptidase IV, as well as membrane-bound aminopeptidase B and pyroglutamyl peptidase I, was measured in these tissues, suggesting a role in the pathophysiology of chronic inflammation. Additionally, aminopeptidase activity is present in human nasal mucosa, where it may influence local peptide signaling and host defense.
Aminopeptidase activity in renal and metabolic disease
In rats with experimental chronic renal failure, aminopeptidase activity in the liver is significantly altered, indicating that uremia or its metabolic consequences affect hepatic peptide processing. This suggests that aminopeptidase activity may be a biomarker or mediator of metabolic disturbances in kidney disease.
Aminopeptidase activity in neurobiology and addiction
A study of postmortem brain tissue from human heroin addicts found changes in aminopeptidase activity compared to controls, implicating these enzymes in neuroadaptive processes associated with opioid addiction. The specific enzymes and brain regions affected may provide clues for future research.
Aminopeptidase activity as a therapeutic target
The aminopeptidase activity of leukotriene A4 hydrolase has been targeted by synthetic diaryl ether modulators, demonstrating that this activity can be selectively inhibited or modulated for therapeutic benefit in inflammatory conditions. This proof-of-concept supports the development of drugs targeting other aminopeptidases.
From aminopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a specific aminopeptidase alter global peptide profiles? | CRISPR knockout cell line followed by mass spectrometry |
| Is a catalytic residue essential for aminopeptidase activity? | Point mutation (e.g., tyrosine to phenylalanine) knock-in |
| Can a disease-associated mutation affect aminopeptidase activity? | Knock-in of patient variants in isogenic cell lines |
| Where is the enzyme localized within the cell? | Tagged knock-in with fluorescent protein for imaging |
| Does overexpression of an aminopeptidase change cell behavior? | Doxycycline-inducible overexpression in cancer cell lines |
| Which genes regulate aminopeptidase activity? | CRISPR library screening with activity-based readout |
How to Study the aminopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Colorimetric/fluorogenic substrate assay | Total aminopeptidase activity in lysates or live cells | Tissue profiling and inhibitor testing |
| Mass spectrometry peptidomics | N-terminal peptide sequences and abundance | Substrate specificity and pathway analysis |
| CRISPR knockout screening | Genes required for aminopeptidase activity | Discovery of novel regulators |
| Western blot | Protein expression levels of specific aminopeptidases | Validation of knockout or overexpression |
| Immunohistochemistry | Tissue distribution of aminopeptidases | Pathology studies |
| Fluorescent tagging and microscopy | Subcellular localization | Live-cell imaging of enzyme dynamics |
| Enzyme kinetics | Km, Vmax, and catalytic efficiency | Characterization of mutants |
| Small-molecule screening | Identification of inhibitors or activators | Drug discovery |
Enzymatic activity assays
Aminopeptidase activity is classically measured using colorimetric or fluorogenic substrates that release a detectable product upon cleavage of the N-terminal residue. These assays have been used to quantify activity in human nasal mucosa, brain tissue, and lymphoid tissues. They can be adapted for high-throughput screening to identify inhibitors or activators.
Proteomics and peptidomics
Mass spectrometry-based proteomics and peptidomics can profile the accumulation or depletion of specific N-terminal peptides following manipulation of aminopeptidase genes. This approach provides a global view of substrate specificity and cellular pathways affected by altered aminopeptidase activity.
CRISPR-based genetic screens
Pooled CRISPR knockout or activation screens coupled with an aminopeptidase activity readout can identify genes that regulate this function. Such screens are powerful for discovering novel components of the aminopeptidase network, as demonstrated by the census of cytosolic aminopeptidases.
Imaging and subcellular localization
Fluorescent tagging of aminopeptidases via knock-in allows visualization of their subcellular distribution and dynamics. This is particularly useful for distinguishing cytosolic, membrane-bound, and secreted forms.
How CRISPR Can Be Used to Study GO:0004177 aminopeptidase activity
Knockout
CRISPR knockout of a specific aminopeptidase gene (e.g., ENPEP, ANPEP, LTA4H) eliminates its contribution to total cellular aminopeptidase activity. This allows researchers to attribute observed phenotypes to a single enzyme and to identify compensatory upregulation of other family members. Knockout cell lines are essential for validating substrate specificity and for disease modeling.
Point Mutation
Point mutations can be introduced to test the role of catalytic residues, such as the essential tyrosine in aminopeptidase A. By mutating this residue to phenylalanine, researchers can abolish activity while preserving protein structure, thereby distinguishing catalytic function from non-catalytic roles. Point mutations can also model human disease variants.
Knock-in
Knock-in of tagged versions (e.g., FLAG, GFP) of aminopeptidase genes enables affinity purification, imaging, and interaction studies. Knock-in of disease-associated alleles allows functional characterization of variants in an isogenic background, providing insights into how specific mutations alter aminopeptidase activity.
Overexpression
Overexpression of a wild-type or mutant aminopeptidase gene can amplify its activity, facilitating biochemical purification and substrate identification. Inducible overexpression systems allow controlled studies of downstream effects on cell signaling, proliferation, and survival. Overexpression is also useful for testing small-molecule modulators.
How EDITGENE Supports aminopeptidase activity Research
Researchers studying aminopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from gene knockout to precise point mutations and knock-in of reporter or disease alleles.
Contact EDITGENE today to design your custom CRISPR model for aminopeptidase activity research.
Frequently Asked Questions About aminopeptidase activity
What is aminopeptidase activity?
Aminopeptidase activity (GO:0004177) is the catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain. It is a molecular function carried out by enzymes that trim the amino terminus of peptides and proteins.
What genes are involved in aminopeptidase activity?
Genes encoding enzymes with this activity include ENPEP (aminopeptidase A), ANPEP (aminopeptidase N), LNPEP, RNPEP, PGPEP1, LTA4H, NPEPPS, ERAP1, ERAP2, METAP1, METAP2, XPNPEP1, XPNPEP2, and others.
How is aminopeptidase activity measured?
It is commonly measured using colorimetric or fluorogenic substrates that release a detectable product upon cleavage of the N-terminal amino acid. Activity has been measured in human tissues such as nasal mucosa, brain, and tonsils.
What diseases are associated with altered aminopeptidase activity?
Altered activity has been observed in inflammatory airway diseases (adenoid hyperplasia, chronic tonsillitis), chronic renal failure, and heroin addiction. Aminopeptidases are also targets in cancer and autoimmune diseases.
Which aminopeptidase has a known essential catalytic residue?
A tyrosine residue essential for catalytic activity has been identified in aminopeptidase A (encoded by ENPEP).
Can aminopeptidase activity be inhibited by drugs?
Yes, small-molecule modulators of leukotriene A4 hydrolase aminopeptidase activity have been synthesized and evaluated, demonstrating that this activity is druggable.
What is the difference between aminopeptidase and dipeptidyl peptidase?
Aminopeptidases remove a single N-terminal amino acid, while dipeptidyl peptidases remove a dipeptide from the N-terminus. Both activities were measured in tonsillar tissues.
Are there cytosolic aminopeptidases?
Yes, a census of cytosolic aminopeptidase activity revealed two novel cytosolic aminopeptidases, expanding the known repertoire.
How can CRISPR be used to study aminopeptidase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to determine the causal role of specific aminopeptidase genes in cellular processes and disease.
What is the GO ID for aminopeptidase activity?
The Gene Ontology ID for aminopeptidase activity is GO:0004177.
Conclusion
Aminopeptidase activity (GO:0004177) is a fundamental molecular function that governs the removal of N-terminal amino acids from peptides and proteins. Its presence across diverse human tissues and its alteration in diseases such as inflammatory airway conditions, chronic renal failure, and addiction highlight its physiological and pathological importance. The identification of essential catalytic residues and the development of small-molecule modulators provide a foundation for therapeutic targeting. CRISPR-based models are indispensable for dissecting the specific roles of individual aminopeptidases and for translating these findings into clinical applications.
References
- 1. Ohkubo K et al.. 1998. Aminopeptidase activity in human nasal mucosa.. J Allergy Clin Immunol 102(5):741-50 PMID: 9819290
- 2. Akkad N et al.. 2012. Census of cytosolic aminopeptidase activity reveals two novel cytosolic aminopeptidases.. Med Microbiol Immunol 201(4):463-73 PMID: 22976555
- 3. Larrinaga G et al.. 2011. Activity of soluble aminopeptidase A and dipeptidyl peptidase IV and membrane-bound aminopeptidase B and pyroglutamyl peptidase I in adenoid hyperplasia, tonsillar hyperplasia and chronic tonsillitis.. Int J Pediatr Otorhinolaryngol 75(11):1399-403 PMID: 21937126
- 4. Larrinaga G et al.. 2005. Aminopeptidase activity in the postmortem brain of human heroin addicts.. Neurochem Int 46(3):213-9 PMID: 15670637
- 5. Petruncio G et al.. 2024. Synthesis and Evaluation of diaryl ether modulators of the leukotriene A(4) hydrolase aminopeptidase activity.. Eur J Med Chem 272:116459 PMID: 38704942
- 6. Vazeux G et al.. 1997. A tyrosine residue essential for catalytic activity in aminopeptidase A.. Biochem J 327 ( Pt 3)(Pt 3):883-9 PMID: 9581570
- 7. Ogura M et al.. 1984. Aminopeptidase activity in the livers of rats with experimental chronic renal failure.. Biochem Int 9(5):621-4 PMID: 6525198
- 8. Erbeznik H et al.. 1997. A novel mammalian high-molecular-weight aminopeptidase.. Arch Biochem Biophys 344(1):228-34 PMID: 9244402
